Paige A Taylor

Dr. Paige A Taylor

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
Paige A TaylorPaige A Taylor
Paige A Taylor
SKStephen F. Kry
Stephen F. Kry
DFDavid S. Followill
David S. Followill

1 May 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
Paige A TaylorPaige A Taylor
Paige A Taylor
SKStephen F. Kry
Stephen F. Kry
PAPaola Alvarez
Paola Alvarez
TKTyler Keith
Tyler Keith
CLCarrie Lujano
Carrie Lujano
DFDavid S. Followill
David S. Followill

25 January 2023 in Radiotherapy and Oncology
Verified
Journal Article
Open access
Paige A TaylorPaige A Taylor
Paige A Taylor
EMElizabeth Miles
Elizabeth Miles
LHLone Hoffmann
Lone Hoffmann
SKSarah M. Kelly
Sarah M. Kelly
SKStephen F. Kry
Stephen F. Kry
CCCatharine H. Clark
Catharine H. Clark
The Global Clinical Trials RTQA Harmonization Group (GHG) set out to evaluate and prioritize clinical trial quality assurance. The GHG compiled a list of radiotherapy quality assurance (QA) tests performed for proton and photon therapy clinical trials. These tests were compared between modalities to assess whether there was a need for different types of assessments per modality. A failure modes and effects analysis (FMEA) was performed to assess the risk of each QA failure. The risk analysis showed that proton and photon therapy shared four out of five of their highest-risk failures (end-to-end anthropomorphic phantom test, phantom tests using respiratory motion, pre-treatment patient plan review of contouring/outlining, and on-treatment/post-treatment patient plan review of dosimetric coverage). While similar trends were observed, proton therapy had higher risk failures, driven by higher severity scores. A sub-analysis of occurrence × severity scores identified high-risk scores to prioritize for improvements in RTQA detectability. A novel severity scaler was introduced to account for the number of patients affected by each failure. This scaler did not substantially alter the ranking of tests, but it elevated the QA program evaluation to the top 20th percentile. This is the first FMEA performed for clinical trial quality assurance. The identification of high-risk errors associated with clinical trials is valuable to prioritize and reduce errors in radiotherapy and improve the quality of trial data and outcomes, and can be applied to optimize clinical radiotherapy QA.

1 October 2017 in International Journal of Particle Therapy
Verified
Journal Article
Open access
DBDaniela Branco
Daniela Branco
Paige A TaylorPaige A Taylor
Paige A Taylor
Xiaodong ZhangXiaodong Zhang
Xiaodong Zhang
HLHeng Li
Heng Li
MGMichele Guindani
Michele Guindani
DFDavid Followill
David Followill
Purpose: To design and commission a head and neck (H&N) anthropomorphic phantom that the Imaging and Radiation Oncology Core Houston (IROC-H) can use to verify the quality of intensity-modulated proton therapy H&N treatments for institutions participating in National Cancer Institute–sponsored clinical trials. Materials and Methods: The phantom design was based on a generalized oropharyngeal tumor, including critical H&N structures (parotid glands and spinal cord). Radiochromic film and thermoluminescent dosimeter (TLD)-100 capsules were embedded in the phantom and used to evaluate dose delivery. A spot-scanning treatment plan with typical clinical constraints for H&N cancer was created by using the Eclipse analytic algorithm. The treatment plan was approved by a radiation oncologist and the phantom was irradiated 4 times. The measured dose distribution using a ±7%/4 mm gamma analysis (85% of pixels passing) and point doses were compared with the treatment planning system calculations. The prescr...

30 July 2021 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
SHShannon Hartzell
Shannon Hartzell
FGFada Guan
Fada Guan
Paige A TaylorPaige A Taylor
Paige A Taylor
CPChristine Peterson
Christine Peterson
PTPhillip Taddei
Phillip Taddei
SKStephen F Kry
Stephen F Kry
Microdosimetry is an important tool for assessing energy deposition distributions from ionizing radiation at cellular and cellular nucleus scales. It has served as an input parameter for multiple common mathematical models, including evaluation of relative biological effectiveness (RBE) of carbon ion therapy. The most common detector used for microdosimetry is the tissue-equivalent proportional counter (TEPC). Although it is widely applied, TEPC has various inherent uncertainties. Therefore, this work quantified the magnitude of TEPC measurement uncertainties and their impact on RBE estimates for therapeutic carbon beams. Microdosimetric spectra and frequency-, dose-, and saturation-corrected dose-mean lineal energy (****) were calculated using the Monte Carlo toolkit Geant4 for five monoenergetic and three spread-out Bragg peak carbon beams in water at every millimeter along the central beam axis. We simulated the following influences on these spectra from eight sources of uncertainty: wall effects, pulse pile-up, electronics, gas pressure, W-value, gain instability, low energy cut-off, and counting statistics. Statistic uncertainty was quantified as the standard deviation of perturbed values for each source. Bias was quantified as the difference between default lineal energy values and the mean of perturbed values for each systematic source. Uncertainties were propagated to RBE using the modified microdosimetric kinetic model (MKM). Variance introduced by statistic sources in y ¯ F and y ¯ D averaged 3.8% and 3.4%, respectively, and 1.5% in y * across beam depths and energies. Bias averaged 6.2% and 7.3% in y ¯ F and y ¯ D , and 4.8% in y * . These uncertainties corresponded to 1.2 ± 0.9% on average in RBE MKM . The largest contributors to variance and bias were pulse pile-up and wall effects. This study established an error budget for microdosimetric carbon measurements by quantifying uncertainty inherent to TEPC measurements. It is necessary to understand how robust the measurement of RBE model input parameters are against this uncertainty in order to verify clinical model implementation.

13 November 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
Paige A TaylorPaige A Taylor
Paige A Taylor
JLJessica Lowenstein
Jessica Lowenstein
DFDavid Followill
David Followill
SKStephen F. Kry
Stephen F. Kry